Study Stopped
The IND was withdrawn
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
1 other identifier
observational
29
1 country
15
Brief Summary
This protocol (NLG0705) provides a mechanism for the 15-year follow-up period that the FDA requires for all participants in gene transfer protocols and assures that adequate follow-up can be maintained for subjects who have received at least one dose of algenpantucel-L.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2017
Typical duration for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 22, 2017
CompletedFirst Posted
Study publicly available on registry
May 24, 2017
CompletedStudy Start
First participant enrolled
September 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 8, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 8, 2020
CompletedApril 12, 2022
April 1, 2022
3.3 years
May 22, 2017
April 4, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Proportion of subjects with adverse events.
Up to 15 years
Survival
Up to 15 years
Eligibility Criteria
Research subjects who have received at least one dose of algenpantucel-L immunotherapy in clinical trials.
You may qualify if:
- Receipt of at least one dose of algenpantucel-L within the past 15 years
- Signed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (15)
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Stanford University Cancer Center
Palo Alto, California, 94305, United States
UF Health Cancer Center
Gainesville, Florida, 32610, United States
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Northwestern University
Chicago, Illinois, 60611, United States
NorthShore University HealthSystem
Evanston, Illinois, 60201, United States
Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana, 46526, United States
University of Louisville
Louisville, Kentucky, 40292, United States
Washington University
St Louis, Missouri, 63110, United States
Oregon Health and Science University
Portland, Oregon, 97239, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
UT Health Cancer Center
San Antonio, Texas, 78229, United States
University of Wisconsin
Madison, Wisconsin, 53792, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 22, 2017
First Posted
May 24, 2017
Study Start
September 1, 2017
Primary Completion
December 8, 2020
Study Completion
December 8, 2020
Last Updated
April 12, 2022
Record last verified: 2022-04